Litigation Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

Docket		Date Filed	2018-03-15
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To	Julien Xavier Neals
Jury Demand	None	Referred To	Leda Dunn Wettre
Parties	TEVA PHARMACEUTICALS INDUSTRIES LTD.
Patents	10,195,214; 8,921,348; 9,829,495; 9,943,526
Attorneys	SARAH ANN SULLIVAN
Firms	Kean University
Link to Docket	External link to docket

Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2018-07-06	15	Amended Complaint	of United States Patent Nos. 8,921,348 (“’348 patent”), 9,829,495 (“’495 patent”), and 9,943,526 … States Patent (10) Patent No.: US 8,921,348 B2 … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 44. … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 52. … US 8,921,348 B2 1	External link to document
2020-06-23	152	Opinion	The ’348 Patent and ’495 Patent, along with U.S. Patent No. 10,195,214 (“the ’214 Patent”), are collectively… regarding patent claims in Plaintiff’s U.S. Patent Nos. 8,921,348 (“the ʼ348 Patent”) and 9,829,495…regarding their request for patent claim construction pursuant to Local Patent Rule 4.5(a). This Court has…treatment by mifepristone.” (’348 Patent at Abstract.) 7 According to the patent, “administration of the same…produce excess cortisol. (’495 Patent at 1:23–24, 2:24– 29.) The ’495 Patent discloses a method to differentially	External link to document
2021-04-09	197	Summary Judgment	Summary Judgment of Infringement of U.S. Patent No. 10,195,214 by CORCEPT THERAPEUTICS, INC.. (Attachments… 15 March 2018 2:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document